Work

Examining Health Disparities in the use of Hematopoietic Cell Transplants for HIV-related Lymphoma

Year: 2026
Type: dissertation
Study design: Observational Study
Abstract: There are over 1.2 million people with HIV (PWH) in the United States, with inequities embedded in the HIV epidemic since its earliest years. Disparities persist across the HIV continuum including screening and diagnosis, treatment, viral suppression, and complications; and are influenced by social determinants of health including race/ethnicity, socioeconomic status, sexual and gender minority status, insurance, and geographic location. As combination antiretroviral therapy (cART) became FDA approved in 1996, HIV became a chronic, manageable disease, resulting in a growing and aging population of PWH. As overall survival in PWH has improved, cancer has emerged as a major comorbidity, yet there is a paucity in published evidence addressing the cancer needs of PWH. Lymphoma is among the most common cancers in PWH, with elevated risk due to underlying immunosuppression and viral co-infections (e.g., Epstein-Barr virus). HCT is a potentially curative treatment modality for relapsed or refractory lymphoma. Despite increased risk for lymphomas, PWH experience barriers to standard cancer care, with little known about access to hematopoietic cell transplantation (HCT) for PWH and the associated clinical care. To address these gaps, this dissertation presents two population-based studies of adults aged 18-79 with first primary lymphoma diagnosed from 1991-2016, with cohorts drawn from a novel linkage between the Center for International Blood and Marrow Transplant Research (CIBMTR), the California Cancer Registry (CCR), and the California Patient Discharge Database (PDD). In Specific Aim 1, we characterize HCT utilization among 6,248 PWH diagnosed with lymphoma following HIV diagnosis. Cumulative incidence methods accounted for the competing risk of death, and multivariable Cox proportional hazards models evaluated the sociodemographic and clinical factors associated with HCT use among PWH. Overall, despite improvements in HCT utilization in the modern cART era, HCT use in PWH remained low and was associated with older age, lower neighborhood socioeconomic status, being single/unmarried, and public insurance. In Specific Aim 2, we tested whether HIV status was associated with differences in treatment burden, hospital utilization, and survival after HCT. We identified 140 HCT recipients with HIV (cases) matched 1:3 to 409 HCT recipients without HIV (controls) on age, sex, lymphoma subtype, stage, HCT type, transplant year, and time from diagnosis to transplant. Adjusted cox models demonstrate no significant differences in 90-day acute complications or hospital utilization, while overall survival was similar at 90-days, 1 year, and 2 years post-HCT. Collectively, the studies in this dissertation demonstrate that while HCT use among PWH with lymphoma has increased in California since the introduction of cART, though sociodemographic disadvantages contribute to lesser utilization. Additionally, the findings from these studies suggest that other factors not measured in these studies, like institutional barriers and societal attitudes (e.g. HIV-related stigma), may drive inequities in access. Importantly, we demonstrated that among otherwise eligible patients with HIV that undergo HCT, HIV was not associated with greater risk of acute renal or liver toxicities, infection/sepsis, increased hospital utilization, or inferior survival. These findings support equitable inclusion of PWH in standard eligibility and referral processes, whereby HIV alone should not preclude HCT therapy.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7221484624
Cites: 116
Cited by:
Related to: 10